A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

EBioMedicine

Volumn 6, Issue , 2016, Pages 126-138

  Srivastava, Shashikant ^a   Pasipanodya, Jotam G ^a   Ramachandran, Geetha ^b   Deshpande, Devyani ^a   Shuford, Stephen ^c   Crosswell, Howland E ^c   Cirrincione, Kayle N ^a   Sherman, Carleton M ^a   Swaminathan, Soumya ^b   Gumbo, Tawanda ^a,b  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^c KIYATEC Inc   (United States)

Author keywords

3D liver hollow fiber model; Disseminated tuberculosis; Hepatotoxicity; Pediatric

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 3A4; ETHAMBUTOL; INTERLEUKIN 8; ISONIAZID; LACTATE DEHYDROGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PARACETAMOL; PLATELET DERIVED GROWTH FACTOR; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; VASCULOTROPIN; TUBERCULOSTATIC AGENT;

ALGORITHM; ANATOMIC MODEL; ANIMAL CELL; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL INTELLIGENCE; CHILD; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA SEQUENCE; THREE DIMENSIONAL ORGANOTYPIC LIVER HOLLOW FIBER; BIOLOGICAL MODEL; CELL LINE; COCULTURE; DRUG EFFECTS; INFANT; NEWBORN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TOXIC HEPATITIS; TOXICITY TESTING; TREATMENT OUTCOME; TUBERCULOSIS;

ACETAMINOPHEN; ANTITUBERCULAR AGENTS; CELL LINE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; HUMANS; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TOXICITY TESTS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84959570654     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.040     Document Type: Article

References (53)

1. Ahmad Z., Fraig M.M., Bisson G.P., Nuermberger E.L., Grosset J.H., Karakousis P.C. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob. Agents Chemother. 2011, 55:1527-1532.
2. Ballet F. Preventing drug-induced liver injury: how useful are animal models?. Dig. Dis. 2015, 33:477-485.
3. Becerra M.C., Swaminathan S. Commentary: a targets framework: dismantling the invisibility trap for children with drug-resistant tuberculosis. J. Public Health Policy 2014, 35:425-454.
4. Breiman L. Bagging predictors. Mach. Learn. 1996, 24:123-140.
5. Breiman L. Random forests. Mach. Learn. 2001, 45:5-32.
6. Bumke M.A., Neri D., Elia G. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study. Proteomics 2003, 3:675-688.
7. Chigutsa E., Pasipanodya J.G., Visser M.E., van Helden P.D., Smith P.J., Sirgel F.A., Gumbo T., McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 2015, 59:38-45.
8. Crowle A.J., Dahl R., Ross E., May M.H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 1991, 59:1823-1831.
9. Deshpande D., Srivastava S., Meek C., Leff R., Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob. Agents Chemother. 2010, 54:1728-1733.
10. Deshpande D., Srivastava S., Meek C., Leff R., Hall G.S., Gumbo T. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob. Agents Chemother. 2010, 54:2534-2539.
11. Devrim I., Olukman O., Can D., Dizdarer C. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Chest 2010, 137:737-738.
12. Dheda K., Gumbo T., Gandhi N.R., Murray M., Theron G., Udwadia Z., Migliori G.B., Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir. Med. 2014, 2:321-338.
13. Donald P.R., Maritz J.S., Diacon A.H. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis 2012, 92:1-8. (Edinb.).
14. Gumbo T., Louie A., Deziel M.R., Parsons L.M., Salfinger M., Drusano G.L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 2004, 190:1642-1651.
15. Gumbo T., Louie A., Deziel M.R., Liu W., Parsons L.M., Salfinger M., Drusano G.L. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 2007, 51:3781-3788.
16. Gumbo T., Louie A., Liu W., Brown D., Ambrose P.G., Bhavnani S.M., Drusano G.L. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 2007, 51:2329-2336.
17. Gumbo T., Dona C.S., Meek C., Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 2009, 53:3197-3204.
18. Gumbo T., Siyambalapitiyage Dona C.S., Meek C., Leff R. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 2009, 53:3197-3204.
19. Gumbo T., Chigutsa E., Pasipanodya J., Visser M., van Helden P.D., Sirgel F.A., McIlleron H. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J. Antimicrob. Chemother. 2014, 69:2420-2425.
20. Gumbo T., Pasipanodya J.G., Wash P., Burger A., McIlleron H. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob. Agents Chemother. 2014, 58:6111-6115.
21. Gumbo T., Pasipanodya J.G., Nuermberger E., Romero K., Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin. Infect. Dis. 2015, 61:S18-S24.
22. Gumbo T., Pasipanodya J.G., Romero K., Hanna D., Nuermberger E. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin. Infect. Dis. 2015, 61:S25-S31.
23. Hiruy H., Rogers Z., Mbowane C., Adamson J., Ngotho L., Karim F., Gumbo T., Bishai W., Jeena P. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J. Antimicrob. Chemother. 2015, 70:1115-1123.
24. Ishimaru Y., Matsunami H. Transient receptor potential (TRP) channels and taste sensation. J. Dent. Res. 2009, 88:212-218.
25. Jenkins H.E., Tolman A.W., Yuen C.M., Parr J.B., Keshavjee S., Perez-Velez C.M., Pagano M., Becerra M.C., Cohen T. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet 2014, 383:1572-1579.
26. Karet F.E. Inherited distal renal tubular acidosis. J. Am. Soc. Nephrol. 2002, 13:2178-2184.
27. Magombedze G., Mulder N. A mathematical representation of the development of Mycobacterium tuberculosis active, latent and dormant stages. J. Theor. Biol. 2012, 292:44-59.
28. Magombedze G., Mulder N. Understanding TB latency using computational and dynamic modelling procedures. Infect. Genet. Evol. 2013, 13:267-283.
29. Manca C., Koo M.S., Peixoto B., Fallows D., Kaplan G., Subbian S. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS ONE 2013, 8.
30. McDermott W., Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 1954, 70:748-754.
31. Momper J.D., Mulugeta Y., Burckart G.J. Failed pediatric drug development trials. Clin. Pharmacol. Ther. 2015, 98:245-251.
32. Nakanishi M., Hata K., Nagayama T., Sakurai T., Nishisho T., Wakabayashi H., Hiraga T., Ebisu S., Yoneda T. Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: a potential mechanism of inflammatory pain. Mol. Biol. Cell 2010, 21:2568-2577.
33. Newton S.M., Brent A.J., Anderson S., Whittaker E., Kampmann B. Paediatric tuberculosis. Lancet Infect. Dis. 2008, 8:498-510.
34. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van D.K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
35. Pasipanodya J., Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 2011, 55:24-34.
36. Pasipanodya J.G., Gumbo T. A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin. Infect. Dis. 2013, 57:21-31.
37. Pasipanodya J.G., McIlleron H., Burger A., Wash P.A., Smith P., Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 2013, 208:1464-1473.
38. Pasipanodya J.G., Nuermberger E., Romero K., Hanna D., Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin. Infect. Dis. 2015, 61:S10-S17.
39. Ramachandran G., Hemanth Kumar A.K., Bhavani P.K., Poorana G.N., Sekar L., Vijayasekaran D., Banu Rekha V.V., Ramesh K.S., Ravichandran N., Mathevan G., Swaminathan S. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int. J. Tuberc. Lung Dis. 2013, 17:800-806.
40. Ramachandran G., Kumar A.K., Bhavani P.K., Kannan T., Kumar S.R., Gangadevi N.P., Banurekha V.V., Sekar L., Ravichandran N., Mathevan G., Sanjeeva G.N., Dayal R., Swaminathan S. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. Antimicrob. Agents Chemother. 2015, 59:1162-1167.
41. Roy B., Ghosh S.K., Sutradhar D., Sikdar N., Mazumder S., Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. 2006, 21:784-786.
42. Rumack B.H., Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975, 55:871-876.
43. Rumack B.H., Peterson R.C., Koch G.G., Amara I.A. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch. Intern. Med. 1981, 141:380-385.
44. Schmalstieg A.M., Srivastava S., Belkaya S., Deshpande D., Meek C., Leff R., van Oers N.C., Gumbo T. The antibiotic-resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug-resistance. Antimicrob. Agents Chemother. 2012, 56:4806-4815.
45. Sevrioukova I.F., Poulos T.L. Current approaches for investigating and predicting cytochrome P450 3A4-ligand interactions. Adv. Exp. Med. Biol. 2015, 851:83-105.
46. Sherry A.M., Cuppoletti J., Malinowska D.H. Differential acidic pH sensitivity of delta F508 CFTR Cl-channel activity in lipid bilayers. Am. J. Physiol. 1994, 266:C870-C875.
47. Srivastava S., Gumbo T. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr. Pharm. Des. 2011, 17:2881-2888.
48. Srivastava S., Musuka S., Sherman C., Meek C., Leff R., Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 2010, 201:1225-1231.
49. Srivastava S., Pasipanodya J.G., Meek C., Leff R., Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect. Dis. 2011, 204:1951-1959.
50. Srivastava S., Sherman C., Meek C., Leff R., Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob. Agents Chemother. 2011, 55:5085-5089.
51. Thee S., Seddon J.A., Donald P.R., Seifart H.I., Werely C.J., Hesseling A.C., Rosenkranz B., Roll S., Magdorf K., Schaaf H.S. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob. Agents Chemother. 2011, 55:5560-5567.
52. Zhang Y., Scorpio A., Nikaido H., Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 1999, 181:2044-2049.
53. Zhang Y., Permar S., Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 2002, 51:42-49.